ACTUATE THERAPEUTICS, INC.
No enriched coverage for $ACTU in the last 7 days.
No SEC Form 4 filings for $ACTU in the last 30 days.
Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
Actuate Therapeutics, Inc. announced promising initial clinical responses in pediatric cancers from its Phase 1 trial of elraglusib, noting two Complete Metabolic Responses in Ewing sarcoma and one Complete Response in neuroblastoma among 40 patients. The company plans to advance elraglusib's clinical development in 2026, especially for Ewing sarcoma, following its Rare Pediatric Designations from the FDA. Clinical responses and disease control were observed in 15 patients, with particular efficacy when elraglusib was combined with cyclophosphamide and topotecan.
CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
Recent ACTU coverage spans financial news and market movers.
A new trial assignment for Elraglusib is a fresh development catalyst that can re-rate risk sentiment.
Actuate Therapeutics reports promising early clinical responses in pediatric cancers, notably in Ewing sarcoma and neuroblastoma. The company plans to advance elraglusib's development, especially for Ewing sarcoma, after receiving FDA Rare Pediatric Designations. The news suggests potential positive impact on ACTU stock, with increased investor interest in oncology therapeutics.
The recent submission of updated clinical data to the FDA suggests progress in regulatory approval process for Actuate Therapeutics' pipeline, potentially leading to positive market sentiment.
Actuate Therapeutics has announced a $15 million public offering, which could lead to short-term stock dilution but may also provide capital for growth initiatives. The neutral sentiment indicates no immediate market bias.
The company's announced $15 million public offering may lead to short-term stock dilution but could also provide capital for growth, influencing stock price accordingly.
alphai scores every news story that mentions ACTU with an AI model for sentiment and relevance, and aggregates insider trades from ACTUATE THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
7 min readActuate Therapeutics, Inc. announced promising initial clinical responses in pediatric cancers from its Phase 1 trial of elraglusib, noting two Complete Metabolic Responses in Ewing sarcoma and one Complete Response in neuroblastoma among 40 patients. The company plans to advance elraglusib's clinical development in 2026, especially for Ewing sarcoma, following its Rare Pediatric Designations from the FDA. Clinical responses and disease control were observed in 15 patients, with particular efficacy when elraglusib was combined with cyclophosphamide and topotecan.
3 min readCHICAGO and FORT WORTH, Texas, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
4 min readCHICAGO and FORT WORTH, Texas, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc.
2 min readCHICAGO and FORT WORTH, Texas, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
2 min readCHICAGO and FORT WORTH, Texas, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
2 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc.
4 min read- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients ...
3 min read- Near doubling of 1-year overall survival ( OS ) , increased median OS of 4 months ( 12.5 vs 8.5 months ) , and 43% reduction in risk of death in patients treated with at least one cycle ( 4 weeks ) of elraglusib plus gemcitabine/nab-paclitaxel ( GnP ) vs GnP alone ...
3 min readPhase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer ( mPDAC ) treated with elraglusib Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer ( mPDAC ) treated with ...
3 min read
